Rasagiline, sold under the brand name Azilect among others, is a medication which is used in the treatment of Parkinson's disease. It is used as a monotherapy...

MAO-B inhibitor and antiparkinsonian agent rasagiline ((R)-N-propargyl-1-aminoindan). In contrast to rasagiline, it lacks significant monoamine oxidase inhibition...

pharmacologically active and is an active metabolite of the antiparkinsonian agent rasagiline. Through its (R)-enantiomer (R)-1-aminoindane, 1-aminoindane has pharmacological...

is less selective for MAO-B inhibition than AGN-1135 (racemic rasagiline) or rasagiline. In addition to its MAOI activity, SU-11739 has been reported...

imipramine, desipramine), monoamine oxidase inhibitors (MAOIs) (e.g., rasagiline), serotonin antagonists and reuptake inhibitors (SARIs) (e.g., nefazodone)...

more potent than D-deprenyl. AGN-1135 (racemic rasagiline) SU-11739 (racemic N-methylated rasagiline) Parnham, M. J. (1993). "The History of l-Deprenyl"...

racemic rasagiline or as N-propargyl-1-aminoindane) is a monoamine oxidase inhibitor (MAOI) that was never marketed. It is the racemic form of rasagiline and...

B propargyl amine inhibitor rasagiline (N-propargyl-1-R-aminoindan, Azilect((R))). The oral bioavailability of rasagiline is 35%, it reaches T(max) after...

Antagonists of MAEs, like EPPTB (a known TAAR1 antagonist), 3-F-BPAP, and rasagiline, have been identified. A few endogenous MAEs have been identified, including...

Parkinson's disease. It was developed from structural modification of rasagiline. The drug acts as a reversible acetylcholinesterase and butyrylcholinesterase...